Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02348008
Title Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Arkadiusz Z. Dudek, MD
Indications

clear cell renal cell carcinoma

Therapies

Bevacizumab + Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University, Robert H. Lurie Cancer Center Chicago Illinois 60611 United States Details
University of Illinois Cancer Center Chicago Illinois 60612 United States Details
University of Iowa, Holden Comprehensive Cancer Center Iowa City Iowa 52242 United States Details
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 United States Details
Michigan State University, Breslin Cancer Center Lansing Michigan 48910 United States Details
University of Minnesota: Masonic Cancer Center Minneapolis Minnesota 55455 United States Details
University of Nebraska, Fred and Pamela Buffet Cancer Center Omaha Nebraska 68198 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Penn State Hershey Cancer Institute Hershey Pennsylvania 17033 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field